In vitro

Scientific research
#Drug discovery #In vitro #mRNA #Webinar

Scaling up in vitro transcription: Key results and considerations

In vitro transcription (IVT) can be a complicated reaction. Scaling up this process requires a good understanding of the various reaction parameters that need to be optimised and controlled to give the best result in terms of mRNA yields and quality. In this presentation, a review of the results from scaling… Read More

Webinar date:
Supported by Thermo Fisher Scientific
#Webinars

Brussels, Belgium
#Biology #Events #Genomics #High Throughput #In vitro #Organ-on-a-chip #Organoids #SLAS #SLAS Europe

SLAS Europe 2023 reveals details of Biology Unveiled track

SLAS Europe has revealed details of the Biology Unveiled track at the upcoming meeting in Brussels, Belgium on May 23-26. The other three tracks are Frontiers in Technology, Shaping the Future of Therapeutics and Bio-Entrepreneurship in Europe. The Biology Unveiled track will feature scientific… Read More

#News

Gelatin biomaterials
#Animal testing #Biomaterials #In vitro #Preclinical investigations #Rousselot Biomedical

Low endotoxin biomaterials could help to reduce animal testing

A new study has found that highly purified gelatin biomaterials could enhance the reliability and reproducibility of 3AD in vitro models, creating new possibilities for replacing preclinical animal trials. The joint study by the University of Twente, The Netherlands, and Rousselot Biomedical investigated for the first… Read More

#News

In vitro diagnostics
#Clinical trials #EFPIA #EU #European Federation of Pharmaceutical Industries and Associations #In vitro #Pharmaceuticals #Regulatory

New EU in vitro regulations delaying clinical trials

New EU legislation designed to improve public health is delaying clinical trials and blocking access to new treatments for cancer and rare diseases, says the European Federation of Pharmaceutical Industries and Associations (EFPIA). The number of clinical trials delayed is expected to run into the hundreds, affecting up to 42,200… Read More

#News #Regulatory

Organ-on-a-chip
#Bioavailability #CN Bio #Collaboration #FDA #In vitro #Organ-on-a-chip

FDA expands organ-on-a-chip research collaboration

The US Food and Drug Administration (FDA) and CN Bio have expanded their collaboration for the second time, with new research aiming to evaluate multi-organ microphysiological systems (MPS) using the PhysioMimix Multi-organ System.   The system will initially be investigated for improving the preclinical estimation of human drug… Read More

#News

Organoids
#Drug development #Drug discovery #Drug screening #Gene editing #In vitro #In vivo #Organoids #Personalised medicine

Gene editing in organoids: accounting for complexity in drug discovery

Oksana Sirenko looks at the advantages and limitations of using organoids from human cell sources in drug development and drug screening.  The genome is the blueprint for life, consisting of genes made up of thousands of pairs of DNA bases. Altering one base pair can drastically change how the gene’s… Read More

#Exclusive Content

In vitro study
#Drug discovery #In vitro #Regulatory

In Vitro Pharmacology Working Group to address data standards

A new In Vitro Pharmacology Working Group to accelerate regulatory submissions has been created by the Pistoia Alliance, a global advocate for greater collaboration in life sciences R&D. The group will include liaisons from the US Food and Drug Administration’s Center for Drug Evaluation and Research, as well as representatives… Read More

#News #Regulatory

Vials for medical research
#Antibodies #Biomedical research #Drug development #Drug discovery #In vitro

New anti-evolocumab antibodies could aid drug development

Bio-Rad Laboratories has introduced a range of type 1 antibodies that inhibit the binding of evolocumab (Repatha) to its target, human proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that has been shown to play a key role in the regulation of cholesterol levels.  These sequence-defined, recombinant antibodies are… Read More

#News

#In vitro #Mitochondria

How to learn new ways to identify mitochondrial liability

Drug-induced mitochondrial dysfunction has been linked to compound attrition, organ toxicity, black-box warnings, and market withdrawals. Agilent has released a mitochondrial toxicity infographic to help you discover the benefits of novel in vitro strategies for consumer safety. This infographic is designed to help: Gain a historical perspective on mitochondrial toxicity. Understand… Read More

#News

#Cytokines #In vitro #In vivo #Research study #Whitepaper

White Paper: A new way to study cytokine release syndrome

An in vivo CRS Evaluation Study in humanised mouse models can deliver fast, reproducible, and translatable data about drug safety in just two weeks. A humanised mouse platform offers the unique ability to preclinically analyse a fully systemic response that involves human immune cells and surrounding tissues. Furthermore, the platform… Read More

#News #Trending News

#Cancer research #In vitro #Oncology #Tumour biology

Self-assembling PeptiGels as a platform to recapitulate the tumour microenvironment in pancreatic cancer 

This paid-for advertorial by Manchester BioGel appeared in the DDW / ELRIG UK Drug Discovery 2021 supplement in DDW Volume 22, Issue 4 – Fall 2021   Communication of cells with their microenvironment is vital in understanding intracellular processes. Most matrices lack the mechanical and biochemical tuneability necessary to recreate the cancer microenvironment. Read More

#Exclusive Content

#Covid-19 #FDA #In vitro

FDA-approved drugs reduced SARS-CoV-2 infection in lab 

An in vitro study of drugs already approved by the US Food and Drug Administration (FDA) to treat a range of conditions has shown eight of them are also effective in slowing SARS-CoV-2 replication in infected human cells. The team led by University of Manchester scientists used the drugs… Read More

#News

#Assay development optimisation & technology #Assays #Drug discovery #Drug toxicity #In vitro #Podcast

Podcast: Paving the way for optimum drug discovery

This is the latest episode of the free DDW podcast, “Paving the way for optimum drug discovery”. It covers two narrated articles written for Volume 22, Issue 1 – Winter 2020/21 of DDW and they are read aloud by Megan Thomas. These articles are titled: “In vitro models for assessing… Read More

#News

#Assays #Drug delivery #Drug discovery #In vitro

Gentronix acquires Big Blue transgenic mutation assay models

UK-based Contract Research Organisation (CRO) Gentronix is set to expand its genetic toxicology capabilities and accelerate its growth following acquisition of the Big Blue transgenic mutation assay models. The acquisition ensures the continuing market provision of the Big Blue transgenic assays for companies requiring mutagenicity assessment under the OECD 488… Read More

#News

#3D modelling #Immunology #In vitro #Microbiome #Research

King’s College London uses CN Bio to investigate chronic liver disease

King’s College London is using CNBio’s PhysioMimix Multi-Organ MPS. Following a research collaboration, King’s College London selected the system to create a human-relevant liver-intestinal model for characterising and manipulating host-microbial interactions, to support improved outcomes in cirrhosis. Launched in March 20211, the product combines CN Bio’s in vitro 3D liver… Read More

#News

#Cancer research #Diagnostics #Drug development #In vitro

Avacta enters diagnostic licensing deal with Biokit

Avacta, developer of cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms, has announced a licensing agreement with Biokit, to incorporate Affimer reagents into a Biokit in-vitro diagnostic (IVD) product. Biokit has experience in research, development and manufacturing of assays and biomaterial solutions for IVD use. Under… Read More

#Cancer Research #News